key: cord-0795137-hz549mg5
authors: Sethia, Rahul; Prasad, Manya; Garg, Pramod Kumar
title: Letter to the editor: Famotidine and mortality in COVID-19
date: 2020-12-31
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.12.045
sha: 10a286e707b02c3c923473dd7f46d00235bfe290
doc_id: 795137
cord_uid: hz549mg5

nan

The supplementary Table 1 mentions the number of patients intubated, receiving mechanical ventilation, and 30-day mortality as 21.4, 27.7, and 72.9, respectively, and to be rechecked.

Their results are in contrast to other published studies. But it is difficult to directly compare their results with those of other studies due to heterogeneity at multiple levels. We conducted a systematic review and meta-analysis of the previously published studies. 7 We searched the databases Medline, Embase, Cochrane CENTRAL, and Medrxiv for title, abstract, and fulltext screening. We calculated pooled hazard ratio and 95% CI for the composite outcome of death and intubation using the Generic Inverse Variance approach. The random-effects model was used to conduct the meta-analysis. We carried out the statistical analysis using Review We believe that this study's results reporting no benefit of famotidine need to be interpreted cautiously. Famotidine is an OTC drug with an excellent safety profile and can be a useful adjunct in mild-moderate disease patients. The discrepancy in the results of Yeramaneni et al. and our meta-analysis calls for a randomized trial during the ongoing pandemic.

J o u r n a l P r e -p r o o f

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report